Some product liability claims under Georgia state law are barred by federal preemption. When federal law occupies the field, conflicts with state law, or creates parallel regulatory requirements, state law claims that would impose duties beyond or in addition to the federal scheme can be preempted. The doctrine operates most forcefully in medical device cases involving devices that received FDA premarket approval and in pharmaceutical cases involving generic drugs.
| Preemption category | Source | Key Supreme Court case |
|---|---|---|
| Medical device (FDA premarket approval) | Medical Device Amendments § 360k | <em>Riegel v. Medtronic</em>, 552 U.S. 312 (2008) |
| Generic drug failure to warn | Hatch-Waxman + federal labeling requirements | <em>PLIVA, Inc. v. Mensing</em>, 564 U.S. 604 (2011) |
| Brand-name drug | Federal labeling vs. state common law | <em>Wyeth v. Levine</em>, 555 U.S. 555 (2009) |
Medical device preemption requires premarket approval and excess state duties #
In Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), the U.S. Supreme Court held that the Medical Device Amendments expressly preempt state common law claims that would impose requirements different from or in addition to federal requirements applicable to medical devices that received FDA premarket approval (PMA).
The doctrine has two essential components:
- The device must have received premarket approval (PMA). Devices cleared through the less rigorous 510(k) process are generally not subject to Riegel preemption.
- The state claim must impose duties different from or in addition to federal requirements. Claims that parallel federal requirements (state law claims based on the manufacturer’s failure to comply with FDA-approved specifications) remain available.
Plaintiffs can pursue “parallel claims” where state law duties match federal requirements, such as a state law claim that the manufacturer failed to manufacture the device in accordance with the FDA-approved specifications. These claims are not preempted because they enforce, rather than supplement, federal requirements.
The Riegel analysis turns on specific federal requirements #
Whether a state claim is preempted under Riegel depends on the specific federal requirements applicable to the device. Courts examine:
- The FDA labeling approved for the device
- The manufacturing specifications approved in the PMA
- The conditions imposed by FDA on the device’s approval
- Any post-approval changes the FDA required
A state law claim asserting that the device should have carried a warning beyond what FDA approved is preempted. A state law claim asserting that the manufacturer failed to include warnings the FDA required is not preempted, because it enforces the federal requirement.
The framework creates an unusual structural feature: medical device plaintiffs must often plead and prove federal regulatory non-compliance as part of their state law claims, to establish that the claim parallels federal requirements rather than imposing additional duties.
Generic drug failure-to-warn claims are largely preempted under PLIVA #
In PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), the U.S. Supreme Court held that state law failure-to-warn claims against generic drug manufacturers are preempted by federal law. The reasoning rests on the federal regulatory scheme for generic drugs: under the Hatch-Waxman Act, generic manufacturers are required to use the same labeling as the brand-name reference drug. They cannot unilaterally strengthen or modify the labeling.
Because federal law makes it impossible for a generic manufacturer to change its label to add the warning a state law claim would require, the state law claim is preempted by impossibility preemption.
The decision has broad consequences:
- Patients injured by generic drugs cannot pursue state law failure-to-warn claims against the generic manufacturer
- The injured patient’s remedies against the brand-name manufacturer (under Wyeth, see below) may not be available because the patient took the generic
- This produces what is sometimes called the “generic drug preemption gap”: patients injured by generic drugs may have no viable state law failure-to-warn remedy
Some plaintiffs in generic drug cases have pursued claims framed differently to avoid PLIVA‘s scope (claims based on the manufacturer’s communications outside labeling, claims based on inactive ingredients). Lower courts have reached different conclusions on these theories, and the law continues to develop.
Brand-name drug failure-to-warn claims generally survive under Wyeth #
In Wyeth v. Levine, 555 U.S. 555 (2009), the U.S. Supreme Court held that state law failure-to-warn claims against brand-name drug manufacturers are not generally preempted by federal labeling requirements. Brand-name manufacturers have the ability under the FDA’s Changes Being Effected (CBE) regulations to unilaterally strengthen their drug labeling without prior FDA approval. State law failure-to-warn claims that would require stronger warnings are therefore not made impossible by federal law.
Wyeth preserves state law claims against brand-name manufacturers in most circumstances, with narrow exceptions where the FDA has specifically rejected the warning the state law would require.
Other federal preemption frameworks affect specific product categories #
Beyond medical devices and pharmaceuticals, federal preemption operates in several other product categories:
- Pesticides: FIFRA preempts some state law claims involving pesticide labeling
- Vehicles: NHTSA standards can preempt state law claims regarding specific safety equipment, though preemption is narrower than in medical devices
- Tobacco: Federal cigarette labeling laws preempt some state law warning claims
- Aviation: Federal aviation regulations preempt some state law claims involving aircraft and aircraft parts
- Boats: Federal Boat Safety Act preempts some state claims regarding boat construction
Each category has its own preemption framework, and the analysis is fact-specific.
Preemption interacts with state product liability theories #
Preemption defenses operate as legal barriers to state law claims. They do not eliminate the underlying injury or change the damages framework; they prevent the plaintiff from pursuing certain state law theories. When preemption applies, plaintiffs must:
- Identify state law claims that parallel federal requirements rather than supplementing them
- Plead and prove federal regulatory non-compliance where parallel claims are available
- Consider alternative defendants not subject to preemption
- In medical device cases, distinguish between PMA-approved devices (preempted) and 510(k)-cleared devices (generally not preempted)
The defenses require careful pre-suit analysis of the regulatory status of the product and the specific federal requirements applicable to it.
Preemption motions are often case-dispositive #
A common outcome. Federal preemption typically operates through Rule 12(b)(6) motions to dismiss or summary judgment motions, and successful preemption can dispose of an entire case before discovery is complete. Plaintiffs in preempted product categories face significant difficulty identifying viable state law claims and may have no path forward if preemption applies broadly.
Pre-suit due diligence on preemption questions is therefore central in cases involving FDA-regulated products, federally regulated vehicles, and other federally regulated product categories.
This article is for informational purposes only and does not constitute legal advice. Personal injury cases turn on specific facts and applicable law that vary by case. If you have been injured in Georgia and want to understand your legal options, consult a licensed Georgia personal injury attorney.